Education and Training
- Fellow In Hematology Oncology, Medicine, Duke University, 2004 - 2007
- Medical Resident, Medicine, University of Texas at Dallas, 2001 - 2004
- M.D., University of North Carolina at Chapel Hill, 2001
Zhang, T, Boswell, EL, McCall, SJ, and Hsu, DS. "Mismatch repair gone awry: Management of Lynch syndrome." Critical reviews in oncology/hematology 93, no. 3 (March 2015): 170-179. (Review)
Bu, P, Wang, L, Chen, KY, Rakhilin, N, Sun, J, Closa, A, Tung, KL, King, S, Kristine Varanko, A, Xu, Y, Huan Chen, J, Zessin, AS, Shealy, J, Cummings, B, Hsu, D, Lipkin, SM, Moreno, V, Gümüş, ZH, and Shen, X. "miR-1269 promotes metastasis and forms a positive feedback loop with TGF-β." Nature communications 6 (January 2015): 6879-.
Ganapathi, AM, Speicher, PJ, Englum, BR, Castleberry, AW, Migaly, J, Hsu, DS, and Mantyh, CR. "Adjuvant chemotherapy for t1 node-positive colon cancers provides significant survival benefit." Diseases of the colon and rectum 57, no. 12 (December 2014): 1341-1348.
Zhang, J, Jima, D, Moffitt, AB, Liu, Q, Czader, M, Hsi, ED, Fedoriw, Y, Dunphy, CH, Richards, KL, Gill, JI, Sun, Z, Love, C, Scotland, P, Lock, E, Levy, S, Hsu, DS, Dunson, D, and Dave, SS. "The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells." Blood 123, no. 19 (May 2014): 2988-2996.
Rangwala, F, Bendell, JC, Kozloff, MF, Arrowood, CC, Dellinger, A, Meadows, J, Tourt-Uhlig, S, Murphy, J, Meadows, KL, Starr, A, Broderick, S, Brady, JC, Cushman, SM, Morse, MA, Uronis, HE, Hsu, SD, Zafar, SY, Wallace, J, Starodub, AN, Strickler, JH, Pang, H, Nixon, AB, and Hurwitz, HI. "Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors." Investigational New Drugs 32, no. 4 (January 1, 2014): 700-709.
Strickler, JH, McCall, S, Nixon, AB, Brady, JC, Pang, H, Rushing, C, Cohn, A, Starodub, A, Arrowood, C, Haley, S, Meadows, KL, Morse, MA, Uronis, HE, Blobe, GC, Hsu, SD, Zafar, SY, and Hurwitz, HI. "Phase i study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer." Investigational New Drugs 32, no. 2 (January 1, 2014): 330-339.
Morse, MA, Niedzwiecki, D, Marshall, JL, Garrett, C, Chang, DZ, Aklilu, M, Crocenzi, TS, Cole, DJ, Dessureault, S, Hobeika, AC, Osada, T, Onaitis, M, Clary, BM, Hsu, D, Devi, GR, Bulusu, A, Annechiarico, RP, Chadaram, V, Clay, TM, and Lyerly, HK. "A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer." Annals of Surgery 258, no. 6 (December 1, 2013): 879-886.
Morse, MA, Chaudhry, A, Gabitzsch, ES, Hobeika, AC, Osada, T, Clay, TM, Amalfitano, A, Burnett, BK, Devi, GR, Hsu, DS, Xu, Y, Balcaitis, S, Dua, R, Nguyen, S, Balint, JP, Jones, FR, and Lyerly, HK. "Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients." Cancer Immunol Immunother 62, no. 8 (August 2013): 1293-1301.
Zani, S, Papalezova, K, Stinnett, S, Tyler, D, Hsu, D, and Blazer, DG. "Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy." J Surg Oncol 107, no. 4 (March 2013): 307-311.
Mettu, NB, Hurwitz, H, and Hsu, DS. "Use of molecular biomarkers to inform adjuvant therapy for colon cancer." ONCOLOGY (United States) 27, no. 8 (2013).